Hopefully this opening from the EMA will further help patients in Europe to have equal access to treatments for oncological diseases as they seem to move in the direction of accepting single arms trials in unique patient populations. https://t.co/rpKDuNHIq7
@US_FDA announced approval of Adstiladrin®, a novel adenovirus vector-based gene therapy, for treatment of adults for high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).
https://t.co/zt9eHaLzLv
#Ferring
Abstract deadline approaching fast July 1st, 2019 for the 2019 Annual IBCN meeting October 3 – 5, 2019 in Aarhus, Denmark. Please visit https://t.co/rpJXoMhRgp… for abstract submission information. #IBCN2019@pcvblack@UroDocAsh@Roland3097@SWilliams_MD